Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:34 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Clinical Trial of Patients With Melanoma
NCT02915666 · University of Texas Southwestern Medical Center · PHASE1 · withdrawn · last registry update 2018-05-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “No subjects consented for enrollment on this study.” | – | Registry record, University of Texas Southwestern Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against BRAF within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-02-04Phase 3 first posted: Institut du Cancer de Montpellier - Val d'Aurelle, Regorafenib + Irinotecan (NCT03829462)
- 2019-01-14Phase 3 first posted: Massachusetts General Hospital, FOLFIRI Protocol + Nivolumab Protocol (NCT03803553)
- 2018-12-21Phase 3 first posted: Institut National de la Santé Et de la Recherche Médicale, France, Nilotinib + Ceritinib (NCT03784014)
- 2018-12-07Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Bevacizumab (NCT03768063)
- 2018-11-28Phase 3 first posted: Exelixis, Cabozantinib + Cabozantinib (NCT03755791)
- 2018-09-26Results posted on the registry: Novartis Pharmaceuticals, Dabrafenib + Trametinib (NCT01682083)
- 2018-08-23Results posted on the registry: Thomas Jefferson University, Ascorbic Acid + Sorafenib + Sorafenib (NCT01754987)
- 2018-06-11Phase 3 first posted: Novartis Pharmaceuticals, Dabrafenib + Trametinib (NCT03551626)
- 2018-05-23Phase 3 first posted: Children's Oncology Group, Carboplatin + Cisplatin (NCT03533582)
- 2018-05-02Results posted on the registry: National Cancer Institute (NCI), Doxorubicin Hydrochloride + Sorafenib Tosylate (NCT01015833)
- 2018-01-26Phase 3 first posted: BeiGene, Tislelizumab + Sorafenib (NCT03412773)
- 2017-10-02Phase 3 first posted: AstraZeneca, Durvalumab + Tremelimumab (Regimen 1) (NCT03298451)
- 2017-06-07Phase 3 first posted: Hoffmann-La Roche, Alectinib + Atezolizumab (NCT03178552)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision